<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01208662</url>
  </required_header>
  <id_info>
    <org_study_id>10-106</org_study_id>
    <nct_id>NCT01208662</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65</brief_title>
  <acronym>DFCI 10-106</acronym>
  <official_title>A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paul G. Richardson, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cape Cod Healthcare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNC Lineberger Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Maine Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ochsner Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>State University of New York - Downstate Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Newton-Wellesley Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huntsman Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The drugs, lenalidomide, bortezomib, and dexamethasone, are approved by the FDA. They have
      not been approved in the combination for multiple myeloma or any other type of cancer.
      Bortezomib is currently approved by the FDA for the treatment of multiple myeloma.
      Lenalidomide is approved for use with dexamethasone for patients with multiple myeloma who
      have received at least one prior therapy and for the treatment of certain types of
      myelodysplastic syndrome (another type of cancer affecting the blood). Dexamethasone is
      commonly used, either alone, or in combination with other drugs, to treat multiple myeloma.
      Please note that Bortezomib and Lenalidomide are provided to patients participating in this
      trial at no charge. Melphalan and cyclophosphamide, the drugs used during stem cell
      collection and transplant, are also approved by the FDA. Melphalan is an FDA-approved
      chemotherapy for multiple myeloma and is used as a high-dose conditioning treatment prior to
      stem cell transplantation. Cyclophosphamide is used, either alone, or in combination with
      other drugs, to treat multiple myeloma. These drugs have been used in other multiple myeloma
      studies and information from those studies suggests that this combination of therapy may help
      to treat newly diagnosed multiple myeloma.

      In this research study, we are looking to explore the drug combination, lenalidomide,
      bortezomib and dexamethasone alone or when combined with autologous stem cell transplantation
      to see what side effects it may have and how well it works for treatment of newly diagnosed
      multiple myeloma. Specifically, the objective of this trial is to determine if, in the era of
      novel drugs, high dose therapy (HDT) is still necessary in the initial management of multiple
      myeloma in younger patients. In this study, HDT as compared to conventional dose treatment
      would be considered superior if it significantly prolongs progression-free survival by at
      least 9 months or more, recognizing that particular subgroups may benefit more compared to
      others.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After screening procedures determine if a patient is eligible for this research study, the
      patient will be randomized into one of the study groups: lenalidomide, bortezomib and
      dexamethasone without autologous stem cell transplantation, followed by lenalidomide
      maintenance (Arm A) or lenalidomide, bortezomib and dexamethasone with autologous stem cell
      transplantation, followed by lenalidomide maintenance (Arm B). There is an equal chance of
      being placed in either group.

      All participants will receive one cycle of lenalidomide, bortezomib and dexamethasone
      treatment before being randomized to Arm A or Arm B.

      Participants in Arm A will receive two additional cycles of lenalidomide, bortezomib and
      dexamethasone prior to stem cell collection. If randomized to Arm A, the subject will undergo
      stem cell collection, followed by five cycles of lenalidomide, bortezomib and dexamethasone.
      This will be followed by lenalidomide maintenance treatment until disease progression.

      Participants in Arm B will receive two additional cycles of lenalidomide, bortezomib and
      dexamethasone prior to stem cell collection. If randomized to Arm B, the subject will undergo
      stem cell collection and autologous stem cell transplantation, followed by two cycles of
      lenalidomide, bortezomib and dexamethasone. This will be followed by lenalidomide maintenance
      treatment until disease progression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <description>To compare progression-free survival (PFS) between Arm A and Arm B.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <description>To compare the response rates (RR) between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <description>To compare time to progression (TTP) between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <description>To compare the overall survival (OS) between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <description>To compare toxicity between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <description>To define genetic prognostic groups evaluated by gene expression profiling (GEP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcomes</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <description>To examine the best treatment in each GEP-defined prognostic group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <description>To compare quality of life (QOL) between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <description>To collect medical resource utilization (MRU) information which may be used in economic evaluation models.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>High Dose Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lenalidomide, bortezomib, dexamethasone. Stem cell collection. Maintenance Lenalidomide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Treatment with SCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide, bortezomib, dexamethasone. Stem cell collection. Autologous Stem Cell Transplant. Maintenance Lenalidomide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Oral, 25 mg/day, days 1-14 for 8 total cycles for Arm A. Oral, 25 mg/day, days 1-14 for 5 total cycles for Arm B.
Oral, 10-15 mg/day, daily for 12 months in maintenance for Arm A and Arm B.</description>
    <arm_group_label>High Dose Treatment</arm_group_label>
    <arm_group_label>High Dose Treatment with SCT</arm_group_label>
    <other_name>CC-5013</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>IV, days 1, 4, 8 and 11 for 8 total cycles for Arm A. IV, days 1, 4, 8 and 11 for 5 total cycles for Arm B.</description>
    <arm_group_label>High Dose Treatment</arm_group_label>
    <arm_group_label>High Dose Treatment with SCT</arm_group_label>
    <other_name>PS-341</other_name>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Oral, days 1, 2, 4, 5, 8, 9, 11 and 12 for 8 total cycles for Arm A. Oral, days 1, 2, 4, 5, 8, 9, 11 and 12 for 5 total cycles for Arm B.
Dose of 20 mg/day for first 3 cycles. Dose of 10 mg/day for remaining cycles.</description>
    <arm_group_label>High Dose Treatment</arm_group_label>
    <arm_group_label>High Dose Treatment with SCT</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Stem Cell Transplant</intervention_name>
    <description>Stem cell transplant</description>
    <arm_group_label>High Dose Treatment with SCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Multiple Myeloma, according to the International Myeloma Foundation 2003
             Diagnostic Criteria

          -  Documented symptomatic myeloma, with organ damage related to myeloma with laboratory
             assessments performed within 21 days of registration

          -  Myeloma that is measurable by either serum or urine evaluation of the monoclonal
             component or by assay of serum free light chains.

          -  ECOG performance status &lt;/= 2

          -  Negative HIV blood test

          -  Voluntary written informed consent

        Exclusion Criteria:

          -  Pregnant or lactating female

          -  Prior systemic therapy for MM (localized radiotherapy allowed if at least 7 days
             before study entry, corticosteroids allowed if dose &lt;/= equivalent of 160 mg
             dexamethasone over 2 weeks)

          -  Primary amyloidosis (AL) or myeloma complicated by amylosis

          -  Receiving any other investigational agents

          -  Known brain metastases

          -  Poor tolerability or allergy to any of the study drugs or compounds of similar
             composition

          -  Platelet count &lt;50,000/mm3, within 21 days of registration

          -  ANC &lt;1,000 cells/mm3, within 21 days of registration

          -  Hemoglobin &lt;8 g/dL, within 21 days of registration

          -  Hepatic impairment (&gt;/= 1.5 x institutional ULN or AST (SGOT), ALT (SGPT), or alkaline
             phosphatase &gt;2 x ULN). Patients with benign hyperbilirubinemia are eligible.

          -  Renal insufficiency (serum creatinine &gt;2.0 mg/dl or creatinine clearance &lt;50 ml/min,
             within 21 days of registration)

          -  Respiratory compromise (DLCO &lt; 50%)

          -  Clinical signs of heart or coronary failure or LVEF &lt; 40%. Myocardial infarction
             within 6 months prior to enrollment, NYHA Class III or IV heart failure, uncontrolled
             angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence
             of acute ischemia or active conductive system abnormalities

          -  Intercurrent illness including, but not limited to ongoing or active severe infection,
             known infection with hepatitis B or C virus, poorly controlled diabetes, severe
             uncontrolled psychiatric disorder or psychiatric illness/social situations that would
             limit compliance with study requirements

          -  Previous history of another malignant condition except for basal cell carcinoma and
             stage I cervical cancer. If malignancy was experienced more than 2 years ago and
             confirmed as cured, these participants may be considered for the study on case by case
             basis with PI discussion.

          -  Inability to comply with an anti-thrombotic treatment regimen

          -  Peripheral neuropathy &gt;/= Grade 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul G. Richardson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul G Richardson, MD</last_name>
    <phone>617-632-2104</phone>
    <email>paul_richardson@dfci.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Racquel Innis Shelton, MD</last_name>
      <phone>205-975-3371</phone>
      <email>Rishelton@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Racquel Innis Shelton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Comprehensive Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amit Agarwal, MD</last_name>
      <phone>520-626-6542</phone>
      <email>aagarwal@uacc.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Amit Agarwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amrita Krishnan, MD</last_name>
      <phone>626-256-4673</phone>
      <email>Akrishnan@coh.org</email>
    </contact>
    <investigator>
      <last_name>Amrita Krishnan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlin Costello, MD</last_name>
      <phone>858-822-6583</phone>
      <email>ccostello@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Caitlin Costello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela Liedtke, MD</last_name>
      <phone>650-498-6000</phone>
      <email>mliedtke@standford.edu</email>
    </contact>
    <investigator>
      <last_name>Michaela Liedtke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey V Matous, MD</last_name>
      <phone>720-754-4800</phone>
      <email>Jeffrey.Matous@HealthONEcares.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey V Matous, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Moreb, MD</last_name>
      <phone>352-273-6845</phone>
      <email>morebjs@medicine.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Jan Moreb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melisa Alsina, MD</last_name>
      <phone>813-745-6886</phone>
      <email>melisa.alsina@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Melisa Alsina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sagar Lonial, MD</last_name>
      <phone>404-727-5572</phone>
      <email>sloni01@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Sagar Lonial, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mountain States Tumor Institute at St. Luke's Regional Medical Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William H Kreisle</last_name>
      <phone>800-845-4624</phone>
    </contact>
    <investigator>
      <last_name>William H Kreisle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ochsner Foundation Clinic</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Emmons, MD</last_name>
      <phone>504-842-3910</phone>
      <email>Remmons@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Robert Emmons, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Maine Medical Center</name>
      <address>
        <city>Brewer</city>
        <state>Maine</state>
        <zip>04412</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Openshaw, MD</last_name>
      <email>topenshaw@emh.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Openshaw, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noopur Raje, MD</last_name>
      <phone>617-726-0711</phone>
      <email>nraje@partners.org</email>
    </contact>
    <investigator>
      <last_name>Noopur Raje, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Richardson, MD</last_name>
      <phone>617-632-2104</phone>
      <email>Paul_Richardson@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Richardson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Avigan, MD</last_name>
      <phone>617-667-9920</phone>
      <email>davigan@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>David Avigan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cape Cod Healthcare</name>
      <address>
        <city>Hyannis</city>
        <state>Massachusetts</state>
        <zip>02601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Basile, MD</last_name>
      <phone>508-862-5799</phone>
      <email>fgbasile@CapeCodHealth.org</email>
    </contact>
    <investigator>
      <last_name>Frank Basile, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newton-Wellesley Hospital</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Block, MD</last_name>
      <phone>617-658-6000</phone>
      <email>cblock@partners.org</email>
    </contact>
    <investigator>
      <last_name>Caroline Block, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Couriel, MD</last_name>
      <email>dcouriel@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Couriel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Zonder, MD</last_name>
      <phone>313-576-8730</phone>
      <email>zonderj@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Zonder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tondre Buck, MD</last_name>
      <phone>601-815-2005</phone>
      <email>tbuck@umc.edu</email>
    </contact>
    <investigator>
      <last_name>Tondre Buck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Hampshire Oncology and Hematology</name>
      <address>
        <city>Concord</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Weckstein, MD</last_name>
      <phone>603-622-6484</phone>
      <email>D.Weckstein@nhoh.com</email>
    </contact>
    <investigator>
      <last_name>Douglas Weckstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Hampshire Oncology and Hematology</name>
      <address>
        <city>Hooksett</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Weckstein, MD</last_name>
      <phone>603-622-6484</phone>
      <email>D.Weckstein@nhoh.com</email>
    </contact>
    <investigator>
      <last_name>Douglas Weckstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Hampshire Oncology and Hematology</name>
      <address>
        <city>Laconia</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Weckstein, MD</last_name>
      <phone>603-622-6484</phone>
      <email>D.Weckstein@nhoh.com</email>
    </contact>
    <investigator>
      <last_name>Douglas Weckstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State University of New York Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gurinder Sidhu, MD</last_name>
      <email>gurinder@downstate.edu</email>
    </contact>
    <investigator>
      <last_name>Gurinder Sidhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myron Czuczman, MD</last_name>
      <phone>716-845-4485</phone>
      <email>Myron.Czuczman@RoswellPark.org</email>
    </contact>
    <investigator>
      <last_name>Myron Czuczman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore Long Island Jewish Health System</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruthee-Lu Bayer, MD</last_name>
      <phone>516-734-8476</phone>
      <email>rbayer@nshs.edu</email>
    </contact>
    <investigator>
      <last_name>Ruthee-Lu Bayer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hani Hassoun, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hani Hassoun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sundar Jagannath, MD</last_name>
      <phone>212-241-7873</phone>
      <email>sundar.jagannath@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Sundar Jagannath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Lentzch, MD</last_name>
      <phone>212-342-3849</phone>
      <email>sl3440@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Suzanne Lentzch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael W Becker, MD</last_name>
      <phone>585-273-3968</phone>
      <email>Michael_Becker@URMC.Rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Michael W Becker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Voorhees, MD</last_name>
      <phone>919-966-5879</phone>
      <email>peter_voorhees@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Voorhees, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Gasparetto, MD</last_name>
      <phone>919-668-1017</phone>
      <email>Gaspa001@mc.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Christina Gasparetto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Hurd, MD</last_name>
      <phone>336-716-4464</phone>
      <email>dhurd@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>David Hurd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Efebera, MD</last_name>
      <phone>614-366-0372</phone>
    </contact>
    <investigator>
      <last_name>Yvonne Efebera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Sciences</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Scott, MD</last_name>
      <email>scottem@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Emma Scott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam D Cohen, MD</last_name>
      <phone>215-615-5853</phone>
      <email>adam.cohen@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Adam D Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mounzer Agha, MD</last_name>
      <phone>412-235-1020</phone>
      <email>Aghame@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Mounzer Agha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Cornell, MD</last_name>
      <phone>615-875-6120</phone>
      <email>robert.f.cornell@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Frank Cornell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larry Anderson, MD</last_name>
      <phone>214-648-5906</phone>
      <email>Larry.Anderson@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Larry Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rammurti Kamble, MD</last_name>
      <phone>713-441-6769</phone>
      <email>RTKamble@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Rammurti Kamble, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Wang, MD</last_name>
      <phone>713-792-2860</phone>
      <email>miwang@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Michael Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Bensinger, MD</last_name>
      <phone>206-667-4933</phone>
      <email>wbensing@fhcrc.org</email>
    </contact>
    <investigator>
      <last_name>William Bensinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2010</study_first_submitted>
  <study_first_submitted_qc>September 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2010</study_first_posted>
  <last_update_submitted>January 19, 2017</last_update_submitted>
  <last_update_submitted_qc>January 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Paul G. Richardson, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lenalidomide</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Stem Cell Transplant</keyword>
  <keyword>Myeloma</keyword>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

